Skip to main content

Closed

GANX: Gain Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-100.0% / yr

Operating margin0.0%

ROIC-130.7%

Financially safe

Stretched

Debt / equity0.05×

Interest coverage0.0×

Current ratio4.69×

Gain Therapeutics, Inc.

GANXNASDAQ Global Market·USD·Closed

Gain Therapeutics, Inc.

GANXNASDAQ·USD·Closed

$1.68

−4.55%

$1.68

−$0.08 (4.55%)

52W Range

9thpctl

Volume

0.27×avg

Mkt Cap

71.66MUSD

P/E

-2.9TTM

Div Yield

–ann

52W Range

9thpctl

Volume

0.27×avg

Market Cap

71.66MUSD

P/E Ratio

-2.9TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings